Ohcanbohtosat - P.V. Plourde

  • Čájehuvvo 1 - 2 / 2
Aiddostahte ozu
  1. 1
    Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

    Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression o... Dahkki Senthil Damodaran, Ciara C. O’Sullivan, Ahmed Elkhanany, Ian C. Anderson, Minal Barve, Sibel Blau, Mathew Cherian, Julio A. Peguero, Matthew P. Goetz, P.V. Plourde, David Portman, H.C.F. Moore

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

    Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial Dahkki Matthew P. Goetz, N.A. Bagegni, Gerald Batist, Adam Brufsky, Massimo Cristofanilli, Senthil Damodaran, B. Daniel, Gini F. Fleming, William J. Gradishar, Stephanie L. Graff, Maria T. Grosse Perdekamp, Erika Hamilton, Sayeh Lavasani, Alvaro Moreno‐Aspitia, Tracey L. O’Connor, Timothy Pluard, Hope S. Rugo, Sarah Sammons, Lee S. Schwartzberg, Daniel G. Stover, Gregory A. Vidal, G. Wang, Ellen Warner, Rinat Yerushalmi, P.V. Plourde, David Portman, Einav Nili Gal‐Yam

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: